| Serial Number | 87528946 |
| Word Mark | AZALTIA |
| Filing Date | Friday, July 14, 2017 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, March 8, 2021 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, December 5, 2017 |
| Goods and Services | Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical blood therapy preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceuticals and medicines for the treatment of central nervous system diseases and disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure diseases and disorders; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, central nervous system (CNS) disorders, neurological disorders, neurodegenerative disorders, and depression; Pharmaceutical neuroprotective agents; antidepressants; antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, medicated toners, medicated moisturizers, medicated rejuvenators, medicated rehydrating creams, and medicated lotions for the face and body |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, July 21, 2017 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Allergan Finance, LLC |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Madison, NJ 07940 |
| Party Name | Allergan Finance, LLC |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Parsippany, NJ 07054 |
| Event Date | Event Description |
| Monday, March 8, 2021 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Monday, March 8, 2021 | ABANDONMENT - NO USE STATEMENT FILED |
| Saturday, August 8, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, August 7, 2020 | EXTENSION 5 GRANTED |
| Friday, July 10, 2020 | EXTENSION 5 FILED |
| Thursday, August 6, 2020 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Friday, July 10, 2020 | TEAS EXTENSION RECEIVED |
| Tuesday, January 28, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, January 24, 2020 | EXTENSION 4 GRANTED |
| Friday, January 24, 2020 | EXTENSION 4 FILED |
| Friday, January 24, 2020 | TEAS EXTENSION RECEIVED |
| Monday, July 8, 2019 | ASSIGNED TO EXAMINER |
| Tuesday, June 11, 2019 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, June 7, 2019 | EXTENSION 3 GRANTED |
| Friday, June 7, 2019 | EXTENSION 3 FILED |
| Friday, June 7, 2019 | TEAS EXTENSION RECEIVED |
| Tuesday, January 22, 2019 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, January 18, 2019 | EXTENSION 2 GRANTED |
| Friday, January 18, 2019 | EXTENSION 2 FILED |
| Friday, January 18, 2019 | TEAS EXTENSION RECEIVED |
| Saturday, July 21, 2018 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Thursday, July 19, 2018 | EXTENSION 1 GRANTED |
| Thursday, July 19, 2018 | EXTENSION 1 FILED |
| Thursday, July 19, 2018 | TEAS EXTENSION RECEIVED |
| Tuesday, January 30, 2018 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, December 5, 2017 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, December 5, 2017 | PUBLISHED FOR OPPOSITION |
| Wednesday, November 15, 2017 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Monday, October 30, 2017 | ASSIGNED TO LIE |
| Friday, October 13, 2017 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, October 13, 2017 | EXAMINER'S AMENDMENT ENTERED |
| Friday, October 13, 2017 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Friday, October 13, 2017 | EXAMINERS AMENDMENT E-MAILED |
| Friday, October 13, 2017 | EXAMINERS AMENDMENT -WRITTEN |
| Thursday, October 5, 2017 | ASSIGNED TO EXAMINER |
| Friday, July 21, 2017 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Tuesday, July 18, 2017 | NEW APPLICATION ENTERED IN TRAM |